By Nicholas G. Miller
Boston Scientific recorded higher third-quarter sales and raised its full-year earnings guidance on the back of continued growth in its cardiovascular segment.
The medical device company logged net income of $755 million, or 51 cents a share, up from $469 million, or 32 cents a share the year prior.
Adjusted earnings were 75 cents a share. Analysts had expected 71 cents, according to FactSet.
Sales rose 20% to $5.07 billion, beating Wall Street's forecast of $4.97 billion. Top-line gains were fueled by the company's cardiovascular segment, which saw 22% net sales growth in the quarter.
The company increased its full-year adjusted earnings guidance to $3.02 to $3.04 a share from its previous forecast of $2.95 to $2.99 a share. Analysts see full-year adjusted earnings of $2.98.
Boston Scientific also guided for fourth-quarter earnings of 77 cents to 79 cents a share. Analysts see 76 cents a share.
Truist analysts said in a note late last month that the company has a diverse and promising product pipeline, fueled by internal development and acquisitions, which should provide strong revenue growth in coming years.
Earlier this month, the company agreed to acquire the rest of Nalu Medical, a medical technology company focused on chronic pain, for $533 million to add to merger agreements earlier this year with SoniVie and Bolt Medical.
Write to Nicholas G. Miller at nicholas.miller@wsj.com.
(END) Dow Jones Newswires
October 22, 2025 06:45 ET (10:45 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.